Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification

Ingrid J. Guldvik; Verena Zuber; Peder R. Braadland; Helene H. Grytli; Håkon Ramberg; Wolfgang Lilleby; Bernd Thiede; Manuela Zucknick; Fahri Saatcioglu; Randi Gislefoss; Rune Kvåle; Anne George; Henrik Grönberg; Fredrik Wiklund; David E. Neal; Vincent J. Gnanapragasam; Kristin A. Taskén; Ian G. Mills

doi:10.1016/j.euros.2020.08.007

Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification

Ingrid J. Guldvik, Verena Zuber, Peder R. Braadland, Helene H. Grytli, Håkon Ramberg, Wolfgang Lilleby, Bernd Thiede, Manuela Zucknick, Fahri Saatcioglu, Randi Gislefoss, Rune Kvåle, Anne George, Henrik Grönberg, Fredrik Wiklund, David E. Neal, Vincent J. Gnanapragasam, Kristin A. Taskén, Ian G. Mills

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

High blood levels of leucine-rich α-2-glycoprotein 1 (LRG1) is unfavourable in patients with newly diagnosed high-risk or metastatic prostate cancer. Implementation of a blood test for LRG1 alongside standard risk stratification schemes could provide higher precision in treatment decisions.

Original language	English
Pages (from-to)	51-60
Number of pages	10
Journal	European Urology Open Science
Volume	21
DOIs	https://doi.org/10.1016/j.euros.2020.08.007
State	Published - Oct 2020
Externally published	Yes

Keywords

Biomarker
Leucine-rich α-2-glycoprotein 1
Noninvasive
Prostate cancer

Access to Document

10.1016/j.euros.2020.08.007

Cite this

Guldvik, I. J., Zuber, V., Braadland, P. R., Grytli, H. H., Ramberg, H., Lilleby, W., Thiede, B., Zucknick, M., Saatcioglu, F., Gislefoss, R., Kvåle, R., George, A., Grönberg, H., Wiklund, F., Neal, D. E., Gnanapragasam, V. J., Taskén, K. A., & Mills, I. G. (2020). Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification. European Urology Open Science, 21, 51-60. https://doi.org/10.1016/j.euros.2020.08.007

@article{002c7c0029ab4b80944f4c2b48907ecc,

title = "Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification",

abstract = "High blood levels of leucine-rich α-2-glycoprotein 1 (LRG1) is unfavourable in patients with newly diagnosed high-risk or metastatic prostate cancer. Implementation of a blood test for LRG1 alongside standard risk stratification schemes could provide higher precision in treatment decisions.",

keywords = "Biomarker, Leucine-rich α-2-glycoprotein 1, Noninvasive, Prostate cancer",

author = "Guldvik, \{Ingrid J.\} and Verena Zuber and Braadland, \{Peder R.\} and Grytli, \{Helene H.\} and H{\aa}kon Ramberg and Wolfgang Lilleby and Bernd Thiede and Manuela Zucknick and Fahri Saatcioglu and Randi Gislefoss and Rune Kv{\aa}le and Anne George and Henrik Gr{\"o}nberg and Fredrik Wiklund and Neal, \{David E.\} and Gnanapragasam, \{Vincent J.\} and Task{\'e}n, \{Kristin A.\} and Mills, \{Ian G.\}",

note = "Publisher Copyright: {\textcopyright} 2020 The Author(s)",

year = "2020",

month = oct,

doi = "10.1016/j.euros.2020.08.007",

language = "Ingl{\'e}s",

volume = "21",

pages = "51--60",

journal = "European Urology Open Science",

issn = "2666-1691",

publisher = "Elsevier BV",

}

Guldvik, IJ, Zuber, V, Braadland, PR, Grytli, HH, Ramberg, H, Lilleby, W, Thiede, B, Zucknick, M, Saatcioglu, F, Gislefoss, R, Kvåle, R, George, A, Grönberg, H, Wiklund, F, Neal, DE, Gnanapragasam, VJ, Taskén, KA & Mills, IG 2020, 'Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification', European Urology Open Science, vol. 21, pp. 51-60. https://doi.org/10.1016/j.euros.2020.08.007

TY - JOUR

T1 - Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification

AU - Guldvik, Ingrid J.

AU - Zuber, Verena

AU - Braadland, Peder R.

AU - Grytli, Helene H.

AU - Ramberg, Håkon

AU - Lilleby, Wolfgang

AU - Thiede, Bernd

AU - Zucknick, Manuela

AU - Saatcioglu, Fahri

AU - Gislefoss, Randi

AU - Kvåle, Rune

AU - George, Anne

AU - Grönberg, Henrik

AU - Wiklund, Fredrik

AU - Neal, David E.

AU - Gnanapragasam, Vincent J.

AU - Taskén, Kristin A.

AU - Mills, Ian G.

PY - 2020/10

Y1 - 2020/10

N2 - High blood levels of leucine-rich α-2-glycoprotein 1 (LRG1) is unfavourable in patients with newly diagnosed high-risk or metastatic prostate cancer. Implementation of a blood test for LRG1 alongside standard risk stratification schemes could provide higher precision in treatment decisions.

AB - High blood levels of leucine-rich α-2-glycoprotein 1 (LRG1) is unfavourable in patients with newly diagnosed high-risk or metastatic prostate cancer. Implementation of a blood test for LRG1 alongside standard risk stratification schemes could provide higher precision in treatment decisions.

KW - Biomarker

KW - Leucine-rich α-2-glycoprotein 1

KW - Noninvasive

KW - Prostate cancer

UR - https://www.scopus.com/pages/publications/85092458436

U2 - 10.1016/j.euros.2020.08.007

DO - 10.1016/j.euros.2020.08.007

M3 - Artículo

AN - SCOPUS:85092458436

SN - 2666-1691

VL - 21

SP - 51

EP - 60

JO - European Urology Open Science

JF - European Urology Open Science

ER -

Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this